Skip to main content


Fig. 3 | Biomarker Research

Fig. 3

From: Development of a fully automated chemiluminescence immunoassay for urine monomeric laminin-γ2 as a promising diagnostic tool of non-muscle invasive bladder cancer

Fig. 3

Dot plot analysis of urine mono-Ln-γ2 with BC, benign urological disease, and HD. Dot plots of creatinine-corrected urine Ln-γ2, (Ln-γ2/crn) in patients with urological diseases. a Dot plots of Ln-γ2/crn in 84 patients with bladder cancer (BC), 48 patients with benign disease, and 105 healthy donors (HDs). The standard deviation values for urinary Ln-γ2 were small in patients with benign diseases and HDs. The distributions of urine Ln-γ2/crn values in patients with BC were significantly higher compared with those from patients with benign disease and HDs (p = 0.0006 and p < 0.0001, respectively). b Dot plots of Ln-γ2/crn in 44 patients with non-muscle invasive BC (NMIBC), nine patients with muscle invasive BC (MIBC), and 105 HDs. The distributions of urine Ln-γ2/crn values in the NMIBC and MIBC groups were significantly higher than those from the healthy donors (p < 0.0001)

Back to article page